Press release
Opioid-Induced Constipation Market Expected to Reach USD 5.4 Billion by 2034
Opioid-Induced Constipation
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71147
With increasing use of opioids in cancer, post-surgical care, and chronic non-cancer pain, OIC has emerged as a significant clinical and market challenge. Patients often discontinue or underuse opioid therapy due to severe constipation, which drives demand for effective OIC-specific treatments. Pharmaceutical innovations, particularly peripherally acting mu-opioid receptor antagonists (PAMORAs), are shaping the future of this market.
Market Overview
• Market Size (2024): USD 2.9 billion
• Forecast (2034): USD 5.4 billion
• CAGR (2025-2034): 6.4%
The opioid-induced constipation market is set for steady expansion, driven by rising opioid prescriptions, growing patient awareness, and increasing adoption of targeted therapies. PAMORAs, including naloxegol, methylnaltrexone, and naldemedine, are gaining traction, while OTC laxatives continue to serve as first-line interventions.
Key Highlights:
• Rising global use of opioids in cancer and chronic pain therapy.
• Increasing demand for OIC-specific therapies to improve patient adherence.
• PAMORAs gaining momentum due to effectiveness in targeting GI opioid receptors.
• OTC laxatives widely used but often insufficient for long-term OIC management.
Segmentation Analysis
By Product Type:
• Over-the-Counter (OTC) Laxatives
o Osmotic Laxatives
o Stimulant Laxatives
• Peripherally Acting Mu-Opioid Receptor Antagonists (PAMORAs)
o Naloxegol
o Methylnaltrexone
o Naldemedine
• Other Prescription Therapies
o Lubiprostone
o Combination Therapies
By Platform:
• Small Molecules
• Biologics
• Combination Formulations
By Technology:
• Oral Formulations
• Injectable Therapies
• Novel Delivery Systems
By End Use:
• Hospitals
• Specialty Clinics
• Retail Pharmacies
• Online Pharmacies
By Application:
• Cancer Pain Management
• Chronic Non-Cancer Pain
• Post-Surgical Pain Care
Segmentation Summary:
OTC laxatives remain widely used but lack targeted efficacy, making PAMORAs the fastest-growing product category. Hospitals and specialty clinics dominate as treatment centers, while retail and online pharmacies play a growing role in improving access to OIC medications.
Explore Full Report here: https://exactitudeconsultancy.com/reports/71147/opioid-induced-constipation-market
Regional Analysis
North America
• Largest market with ~42% share in 2024.
• High opioid prescription rates in the U.S. drive OIC treatment demand.
• Strong adoption of PAMORAs supported by favorable reimbursement.
Europe
• Accounts for ~27% market share.
• Widespread use of opioids in cancer pain therapy sustains market growth.
• Germany, UK, and France lead in adoption of advanced prescription therapies.
Asia-Pacific
• Fastest-growing region with CAGR of ~7.2%.
• Increasing cancer prevalence and improving healthcare access in China, Japan, and India.
• Rising awareness about opioid side effects fueling treatment uptake.
Middle East & Africa
• Smaller market, limited by opioid availability and access to specialty care.
• Gradual growth with expanding hospital infrastructure.
Latin America
• Brazil and Mexico drive growth due to increasing cancer and chronic pain cases.
• Gradual adoption of PAMORAs alongside OTC laxatives.
Regional Summary:
North America leads due to its high opioid use and strong access to OIC therapies, while Asia-Pacific shows the strongest growth potential as awareness and healthcare access expand.
Market Dynamics
Key Growth Drivers:
• Rising global opioid prescription rates for pain management.
• Growing cancer prevalence increasing demand for supportive OIC treatment.
• Expansion of PAMORAs offering targeted relief.
• Strong support from clinical guidelines recommending OIC-specific therapy.
Key Challenges:
• High cost of PAMORA therapies compared to OTC laxatives.
• Limited awareness in emerging markets.
• Dependence on generic laxatives despite limited long-term efficacy.
• Regulatory restrictions on opioid use affecting market growth in some regions.
Latest Trends:
• Development of fixed-dose combination therapies (opioid + OIC management).
• Expansion of biologics and targeted small molecules for GI opioid receptor modulation.
• Growing role of e-commerce and digital platforms in OIC drug distribution.
• Integration of AI and digital health tools for monitoring opioid side effects.
Get Your Exclusive Offer with up to 10% Discount :
https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=71147
Competitor Analysis
Major Players in the Market:
• AstraZeneca plc (Naloxegol)
• Takeda Pharmaceutical Company Limited (Naldemedine)
• Bausch Health Companies Inc. (Relistor - Methylnaltrexone)
• Mallinckrodt Pharmaceuticals
• Pfizer Inc.
• Johnson & Johnson Services, Inc.
• AbbVie Inc.
• Novartis AG
• Teva Pharmaceutical Industries Ltd.
• Dr. Reddy's Laboratories
Competitive Summary:
The OIC market is moderately consolidated, with AstraZeneca, Takeda, and Bausch Health leading in PAMORA therapies. Generic players like Teva and Dr. Reddy's dominate the OTC laxative space. Competition is intensifying as companies focus on expanding distribution, gaining regulatory approvals, and investing in fixed-dose and combination therapies for OIC.
Conclusion
The Opioid-Induced Constipation Market, valued at USD 2.9 billion in 2024, is projected to reach USD 5.4 billion by 2034, growing at a CAGR of 6.4%. With rising opioid use for pain management, OIC-specific therapies are gaining recognition as essential components of supportive care.
Key Takeaways:
• PAMORAs represent the fastest-growing product category, offering targeted efficacy.
• North America leads the market, while Asia-Pacific shows the highest growth potential.
• OTC laxatives dominate in volume but face limitations in treating OIC.
• Strategic innovations in biologics, fixed-dose combinations, and digital health will shape future opportunities.
Over the next decade, the OIC market will transition from reliance on traditional laxatives to specialized, targeted therapies, significantly improving patient outcomes and adherence to opioid pain management.
This report is also available in the following languages : Japanese (オピオイド誘発性便秘市場), Korean (오피오이드 유발 변비 시장), Chinese (阿片类药物引起的便秘市场), French (Marché de la constipation induite par les opioïdes), German (Markt für opioidbedingte Verstopfung), and Italian (Mercato della stitichezza indotta da oppioidi), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/reports/71147/opioid-induced-constipation-market#request-a-sample
Our More Reports:
Basal Cell Carcinoma Market
https://exactitudeconsultancy.com/reports/71371/basal-cell-carcinoma-market
Burn Pain Market
https://exactitudeconsultancy.com/reports/71373/burn-pain-market
Chronic Hand Eczema Market
https://exactitudeconsultancy.com/reports/71375/chronic-hand-eczema-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Opioid-Induced Constipation Market Expected to Reach USD 5.4 Billion by 2034 here
News-ID: 4159787 • Views: …
More Releases from Exactitude Consultancy
Viral Vector Manufacturing Market to Surge to USD 43.04 Billion by 2034, Growing …
Introduction
The healthcare industry is entering a transformative era where precision therapies are reshaping how we treat diseases. Among the most groundbreaking innovations, viral vectors have emerged as critical enablers of gene and cell therapies. These engineered viruses act as vehicles to deliver therapeutic genetic material directly into patients' cells, making them indispensable for modern medicine. From treating rare genetic disorders to powering revolutionary CAR-T cell therapies in oncology, viral vectors…
Veterinary Vaccines Market to Reach USD 20.65 Billion by 2034, Growing at 6.4% C …
Introduction
Animal health is a cornerstone of global food security, sustainable agriculture, and public health. With rising concerns over zoonotic diseases, antimicrobial resistance, and livestock productivity, the role of veterinary vaccines has never been more critical. These vaccines not only protect animal populations from infectious diseases but also indirectly safeguard humans by preventing disease transmission from animals.
In 2024, the global Veterinary Vaccines Market is valued at USD 11.25 billion and is…
Intravenous Immunoglobulin (IVIG) Market to Reach USD 27.1 Billion by 2034, Grow …
Introduction
In recent years, the healthcare industry has seen significant progress in therapies targeting immune system disorders and rare diseases. At the forefront of these therapies is Intravenous Immunoglobulin (IVIG) - a plasma-derived product containing antibodies that play a crucial role in strengthening or modulating immune response. IVIG is widely used in treating primary and secondary immunodeficiency disorders, autoimmune diseases, neurological disorders, and hematological conditions.
With the rising prevalence of chronic illnesses,…
Lipid Nanoparticle Manufacturing Market to Reach USD 2.48 Billion by 2034, Growi …
Introduction
The pharmaceutical and biotechnology industries are undergoing a paradigm shift driven by the success of mRNA vaccines and the growing promise of gene therapies. At the heart of these breakthroughs are lipid nanoparticles (LNPs) - tiny, lipid-based carriers that safely deliver nucleic acids like mRNA, siRNA, and DNA into target cells. LNPs are now recognized as the gold standard for nucleic acid delivery, fueling advancements in infectious disease prevention, oncology,…
More Releases for OIC
Opioid-Induced Constipation (OIC) Drug Market Will Generate Record Revenue by 20 …
Opioid-Induced Constipation (OIC) Drug Market is anticipated to grow at a significant CAGR during the forecast period. The major factor that is expected to boost the market growth includes rising number of geriatric patients as these patients use opioid analgesics such as morphine, hydromorphone, codeine, etc. as a prescription for chronic non-cancer pain which has severe adverse effects on the digestive system resulting in huge demand for OIC drugs. For…
Targeted Treatment Options For Opioid-Induced Constipation (OIC) In Global Marke …
Opioids are prescription drugs taken for treatment of chronic pain. While they relieve the pain, they can give opioid-induced constipation. The adverse effects associated with the opioids are decreasing gastrointestinal tract’s motility, making patient’s strain, and making of solid discharges. Adults are most likely to prone to opioid-induced constipation owing to less immobility, poor diet, and fluid intake.
The opioid-induced constipation treatment market is growing at a significant rate owing…
Opioid-Induced Constipation (OIC) - Pipeline Review, H2 2018 - Research By Marke …
Opioid-Induced Constipation (OIC) - Pipeline Review, H2 2018, provides an overview of the Opioid-Induced Constipation (OIC) (Toxicology) pipeline landscape.
Opioid-Induced Constipation (OIC) - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Opioid-Induced Constipation (OIC) (Toxicology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its…
Opioid-Induced Constipation (OIC) - Complete Analysis on Therapeutics by Stage o …
A new research document is added in HTF MI database of 64 pages, latest Pharmaceutical and Healthcare disease pipeline guide Opioid-Induced Constipation (OIC) - Pipeline Review, H2 2018, provides an overview of the Opioid-Induced Constipation (OIC) (Toxicology) pipeline landscape.
Opioids are effective pain relievers, but often have the side effect of constipation. These medicines affect the gastrointestinal tract in a variety of ways. Opioids increase the amount of time it takes…
Opioid-Induced Constipation (OIC) - Pipeline Review, H1 2017
ReportsWorldwide has announced the addition of a new report title Opioid-Induced Constipation (OIC) - Pipeline Review, H1 2017 to its growing collection of premium market research reports.
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Opioid-Induced Constipation (OIC) - Pipeline Review, H1 2017, provides an overview of the Opioid-Induced Constipation (OIC) (Oncology) pipeline landscape.
Opioids are effective pain relievers, but often have the side effect of constipation. These medicines affect…
Opioid-Induced Constipation (OIC) - Pipeline Review, H2 2016
Global Markets Directs, Opioid-Induced Constipation (OIC) - Pipeline Review, H2 2016, provides an overview of the Opioid-Induced Constipation (OIC) pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Opioid-Induced Constipation (OIC), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development…
